Extended Data Fig. 8: Suppression of AD patholog by lithium orotate.
From: Lithium deficiency and the onset of Alzheimer’s disease
a,b, Immunolabeling of Aβ (a) and pSer202-tau (p-tau/CP13, b) and quantification of Aβ plaque burden (a, right) and CP13+ cell density (b, right) in the hippocampus of 3xTg mice treated with the indicated concentrations of LiO, LiC, NaO or vehicle (water) from 5–12 months of age. c, Immunolabeling and quantification (right) of postsynaptic PSD-95 in hippocampus CA1 of 3xTg mice administered LiO or LiC (4.3 µEq/L), or vehicle from 9–18 months of age. d,e, Immunolabeling of myelin basic protein (MBP) (d) and oligodendrocytes (Aspartoacylase labeling) and quantifications of MBP expression (d, right) and oligodendrocyte density (e, right) in the corpus callosum of 3xTg mice. f,g, Quantification of Iba1+ microglia (f) and GFAP+ astrocyte (g) densities in the hippocampus of 18-month-old 3xTg mice treated with LiO or LiC (4.3 µEq/L) or vehicle from 9–18 months of age. Box plots show individual values, median (line), box limits (25th-75th percentiles), and whiskers (min-max). a-g, Data was normalized to the vehicle group means and analyzed by one-way ANOVA with Tukey’s post-hoc test. Scale bars, 25 μm. a,b, vehicle n = 17, LiO 4.3 n = 17, LiO 43 n = 8, LiO 430 n = 15, LiC 430 n = 10, NaO 4.3 n = 8, NaO 430 n = 6. c-g, water n = 4 (c), n = 6 (d-f), n = 7 (g); LiC n = 8, LiO n = 8.
